Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Trial Profile

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms ESCORT-DM
  • Most Recent Events

    • 19 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top